NAMUR, Belgium, May 26, 2017
/PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it is scheduled to present at multiple investor conferences
in June.
Dr. Scott Powell, Executive Vice President of Volition, will provide an update on Volition's
business, clinical, regulatory and operational milestones, as well as the Company's product launch of its Nu.QTM
Colorectal Cancer Screening Triage Test.
Details of the conferences are as follows
|
Conference:
|
6th Annual SeeThruEquity Microcap Investor Conference
|
|
Date:
|
Thursday, June 1, 2017
|
|
Location:
|
Convene Conference Center, New York, NY
|
|
|
|
Conference:
|
LD Micro Invitational
|
|
Date:
|
Wednesday, June 7, 2017
|
|
Time:
|
10:30 a.m. PDT
|
|
Location:
|
Luxe Sunset Bel Air Hotel, Los Angeles, CA
|
|
|
|
Conference:
|
2017 Marcum MicroCap Conference
|
|
Date:
|
Friday, June 16, 2017
|
|
Time:
|
10:00 a.m. EDT
|
|
Location:
|
Grand Hyatt Hotel, New York, NY
|
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management
during such conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of Volition, at S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately
diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with
additional offices in London, New York, Texas, and Singapore, as the company focuses on bringing its diagnostic
products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release
are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-multiple-investor-conferences-in-june-300464334.html
SOURCE VolitionRx Limited